On March 9, 2018 -AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, reported the presentation of in vivo preclinical data showing AB-PA01 reduces biofilm in a Pseudomonas aeruginosa preclinical model (Press release, AmpliPhi Biosciences, MAR 9, 2018, View Source [SID1234524600]). The data were presented at the Australian Society of Otolaryngology Head and Neck Surgery 68th Annual Scientific Meeting, being held March 9-11, 2018 in Perth, Western Australia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled "Efficacy and safety of a Pseudomonas aeruginosa bacteriophage cocktail in a sheep model of rhinosinusitis" will be delivered by Dr. Stephanie Fong on Saturday, March 10, 2018, at 1:40 p.m. local time in Crown Ballroom 1, Concurrent Session 10 – Rhinology, at the Crown Perth Convention Centre.

"The data presented demonstrate the potential of bacteriophage therapeutics by clearly showing AB-PA01’s effectiveness in reducing biofilm in vivo, a major obstacle in the treatment of Pseudomonas aeruginosa and its associated symptoms," said Peter-John Wormald, M.D., Professor of Otolaryngology Head & Neck Surgery at the University of Adelaide and Principal Investigator for AmpliPhi’s already completed Phase 1 study, "I believe bacteriophage therapeutics hold much promise and this study adds to the growing body of supportive evidence."

A sheep rhinosinusitis model was adapted to simulate Pseudomonas aeruginosa infection in sheep frontal sinuses. To assess efficacy, after a 7-day biofilm formation period, sheep received twice-daily flushes of AB-PA01 or saline for one week. Biofilm quantitation on the frontal sinus mucosa was performed using BacLight LIVE/DEAD stain. The study showed a statistically significant reduction in biofilm biomass with AB-PA01 compared to control (p<0.05). No safety concerns were noted